Mereo BioPharma Group plc Asset Resilience Ratio
Mereo BioPharma Group plc asset resilience ratio. Mereo BioPharma Group plc (MAH0) has an Asset Resilience Ratio of 0.00% as of June 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MAH0 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Mereo BioPharma Group plc (2017–2019)
Asset resilience ratio of Mereo BioPharma Group plc from 2017 to 2019. This chart shows how Mereo BioPharma Group plc's Asset Resilience Ratio has changed over time. Read Mereo BioPharma Group plc (MAH0) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Mereo BioPharma Group plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see MAH0 total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Mereo BioPharma Group plc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Mereo BioPharma Group plc Industry Peers by Asset Resilience Ratio
Compare Mereo BioPharma Group plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Mereo BioPharma Group plc Asset Resilience Ratio by Year (2017–2019)
Mereo BioPharma Group plc asset resilience ratio by year from 2017 to 2019. The table below shows the annual Asset Resilience Ratio data for Mereo BioPharma Group plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 0.00% | €0.00 ≈ $0.00 |
€86.45 Million ≈ $101.07 Million |
-- |
| 2018-12-31 | 3.72% | €2.50 Million ≈ $2.92 Million |
€67.28 Million ≈ $78.65 Million |
+1.12pp |
| 2017-12-31 | 2.60% | €2.50 Million ≈ $2.92 Million |
€96.34 Million ≈ $112.63 Million |
-- |
About Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung dise… Read more